Certara (NASDAQ:CERT) Releases Quarterly Earnings Results

Certara (NASDAQ:CERT) issued its quarterly earnings data on Wednesday. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02, Briefing.com reports. The business had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.06 earnings per share. Certara updated its FY24 guidance to $0.41-0.44 EPS and its FY 2024 guidance to 0.410-0.440 EPS.

Certara Trading Up 0.4 %

Shares of NASDAQ CERT traded up $0.04 during midday trading on Friday, reaching $11.03. 1,081,810 shares of the stock were exchanged, compared to its average volume of 786,430. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The business has a 50-day simple moving average of $11.02 and a two-hundred day simple moving average of $13.70. Certara has a 12 month low of $9.99 and a 12 month high of $19.87. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -22.06, a P/E/G ratio of 4.88 and a beta of 1.51.

Insiders Place Their Bets

In other news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of research reports. Robert W. Baird cut their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Finally, Barclays lowered their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.